Sodium-glucose cotransporter-2 inhibitors and major adverse cardiovascular outcomes: a SMART-C collaborative meta-analysis por Patel, SM, Kang, YM, Im, K, Neuen, BL, Anker, SD, Bhatt, DL, Butler, J, Cherney, DZI, Claggett, BL, Fletcher, RA, Herrington, WG, Inzucchi, SE, Jardine, MJ, Mahaffey, KW, McGuire, DK, McMurray, JJV, Neal, B, Packer, M, Perkovic, V, Solomon, SD, Staplin, N, Vaduganathan, M, Wanner, C, Wheeler, DC, Zannad, F, Zhao, Y, Heerspink, HJL, Sabatine, MS, Wiviott, SD

Long-term effects of empagliflozin in patients with chronic kidney disease por Herrington, WG, Staplin, N, Agrawal, N, Wanner, C, Green, JB, Hauske, SJ, Emberson, JR, Preiss, D, Judge, P, Zhu, D, Dayanandan, R, Arimoto, R, Mayne, KJ, Ng, SYA, Sammons, E, Hill, M, Stevens, W, Wallendszus, K, Brenner, S, Cheung, AK, Liu, Z-H, Li, J, Hooi, LS, Liu, W, Kadowaki, T, Nangaku, M, Levin, A, Cherney, DZI, Maggioni, AP, Pontremoli, R, Deo, R, Goto, S, Rossello, X, Tuttle, KR, Steubl, D, Massey, D, Brueckmann, M, Landray, MJ, Baigent, C, Haynes, R